About this Research Topic
This Research Topic is the second volume of the “Reducing Adverse Effects of Cancer Immunotherapy” Community Series. Please see Volume I here.
Chemotherapy and/or radiotherapy remain the main treatment options for most cancers. However, cancer treatment is associated with numerous adverse effects, including fatigue, stress, hair loss, pain, nausea, vomiting, anemia, altered immune system, oral and intestinal mucositis, which significantly affect patients' quality of life. In addition, the adverse effects may be associated with additional costs, morbidity, and mortality that affect various aspects of the patient's life, including physical health and emotional state.
The management and reduction of adverse effects are extremely important and complex and are primarily aimed at providing comfort to the patient during chemotherapy treatment. In addition, it is important to note that in some cases, the severity of side effects associated with cancer treatment may result in the need to reduce the dose, which in turn may be associated with a reduction in the therapeutic efficacy. In view of this, the identification of new options aimed at alleviating the side effects and increasing the tolerability of oncological treatment is necessary to ensure the quality of life of cancer patients.
We welcome original articles (basic, translational, or clinical research, including studies with cells, animals and alternative research models), mini-reviews, reviews, commentaries, and perspectives that explore, but are not limited to, new treatment options, and therapeutic or preventive alternatives for side effects resulting from oncologic treatment.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Chemotherapy and/or radiotherapy remain the main treatment options for most cancers. However, cancer treatment is associated with numerous adverse effects, including fatigue, stress, hair loss, pain, nausea, vomiting, anemia, altered immune system, oral and intestinal mucositis, which significantly affect patients' quality of life. In addition, the adverse effects may be associated with additional costs, morbidity, and mortality that affect various aspects of the patient's life, including physical health and emotional state.
The management and reduction of adverse effects are extremely important and complex and are primarily aimed at providing comfort to the patient during chemotherapy treatment. In addition, it is important to note that in some cases, the severity of side effects associated with cancer treatment may result in the need to reduce the dose, which in turn may be associated with a reduction in the therapeutic efficacy. In view of this, the identification of new options aimed at alleviating the side effects and increasing the tolerability of oncological treatment is necessary to ensure the quality of life of cancer patients.
We welcome original articles (basic, translational, or clinical research, including studies with cells, animals and alternative research models), mini-reviews, reviews, commentaries, and perspectives that explore, but are not limited to, new treatment options, and therapeutic or preventive alternatives for side effects resulting from oncologic treatment.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords: Chemotherapy side effects, radiotherapy side effects, chemotherapy toxicity, cancer treatment toxicity, chemotherapy tolerability
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
